NM201: A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated with Carbidopa/Levodopa and NE3107

Grants and Contracts Details

StatusActive
Effective start/end date4/7/224/6/23

Funding

  • Cognitive Research Corporation: $2.00